FMCG firm RB India (erstwhile Reckitt Benckiser) aims to expand its market share in pain relief segment with its brand Moov.
The company on Thursday launched a new Diclofenac range of Moov with stronger formulation.
"Its a fragmented market. We have 12 to 13 per cent market share and the market leadership, which we have in cream segment.
"We believe that with the introduction of Diclofenac range of Moov, we will see a significant jump in share numbers. We have high expectation on this," RB HealthSouth Asia Chief Marketing Officer Pankaj Duhan told PTI.
The pain relief market is estimated to be around Rs 4,200 crore, which includes all forms of products in cream, gel, spray and balm.
RB has partnered the government's Fit India Movement to raise awareness on growing new age lifestyle pains.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app